We Need a New Prozac: The Demand for Brain Drug Innovation
[et_pb_section fb_built=”1″ _builder_version=”4.17.6″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.17.6″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.6″ _module_preset=”default” global_colors_info=”{}”][et_pb_post_title meta=”off” featured_image=”off” _builder_version=”4.17.6″ _module_preset=”default” global_colors_info=”{}”][/et_pb_post_title][et_pb_text _builder_version=”4.17.6″ _module_preset=”default” global_colors_info=”{}”]...
Mental Health Champions: Why & How Dr. Emer Leahy of PsychoGenics Is Helping To Champion Mental Wellness
By Yitzi Weiner · Aug. 14, 2022 · Medium Delegate and accept imperfection — I find myself getting anxious when...
The CNS Drug Development Drum Beat is Getting Louder
By Brian Buntz | August 1, 2022 [image courtesy of Pixabay] The late 1980s and the 1990s were something of a gold rush...
GBR Connect Series – Interview with Emer Leahy, PsychoGenics
Can you give an overview of how business has evolved for PsychoGenics over the past year? There are two sides...